Amarin highlights REDUCE-IT post hoc study linking icosapent ethyl to lower tissue factor levels, fewer CV events

• Amarin highlighted new post hoc clinical analyses from REDUCE-IT presented at the ESC Congress 2026.
• Data reinforced that icosapent ethyl lowered cardiovascular events in high-risk, statin-treated patients, including those with chronic kidney disease.
• Mechanistic results presented at the meeting linked EPA to reduced oxidation of atherogenic lipoproteins and to anticoagulation-related pathway effects.
• The 2026 ESC-ERA guideline cited REDUCE-IT RENAL evidence, supporting use of icosapent ethyl to reduce cardiovascular risk in appropriate patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608310815PRIMZONEFULLFEED9818156) on August 31, 2026, and is solely responsible for the information contained therein.